Immunotherapeutic strategies in non-small-cell lung cancer: the present and the future

For the past decades, survival rates for most cancers have improved due to new developments in screening, surgery and systemic therapy. Nevertheless, non-small-cell lung cancer (NSCLC) remains the leading cause of cancer deaths worldwide [1,2]. Most patients are diagnosed in advanced stage and are incurable at the moment of diagnosis, with survival for late-stage NSCLC having only marginally improved over the last decades [2].